CNBC January 14, 2026
Annika Kim Constantino

Key Points

– Novo Nordisk CEO Mike Doustdar said 2026 will be the year of “price pressure” as more GLP-1 supply enters the market and pricing deals take effect.

– Bristol Myers Squibb CEO Chris Boerner said the company has the potential to deliver up to 10 new products by the end of the decade.

– Pfizer CEO Albert Bourla said the company is “all in on obesity.”

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference — the biggest gathering of biotech and pharma execs, investors...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Related Articles:
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
Biotech investor Cormorant secures $150M for another SPAC deal
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety

Share Article